CHMP Recommends Marketing of Biologic for Atopic Dermatitis CHMP Recommends Marketing of Biologic for Atopic Dermatitis

Lebrikizumab is a monoclonal antibody that binds to cytokine IL-13, which has been implicated in driving the type-2 inflammatory loop in the skin, leading to skin barrier dysfunction.MDedge News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Dermatology News Source Type: news